Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience

Y. T. Lim,T. C. Williams,R. J. Langley,E. Weir

DOI: https://doi.org/10.1080/02770903.2024.2303767

2024-01-26

Journal of Asthma

Abstract:Background Mepolizumab is an anti-interleukin-5 monoclonal antibody shown to reduce asthma exacerbations in adults and adolescents with severe eosinophilic asthma.

allergy,respiratory system

What problem does this paper attempt to address?

Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature

Marco Maglione,Melissa Borrelli,Alessandro Dorato,Chiara Cimbalo,Luigi Antonio Del Giudice,Francesca Santamaria

DOI: https://doi.org/10.3390/children11080895

2024-07-25

Abstract:Background: Although, in most children with asthma, good symptom control is achieved with a low to moderate dose of inhaled corticosteroids, a small group of patients still experiences frequent symptoms, and even severe exacerbations, impairment of lung function, and reduced quality of life. Some of these subjects with severe asthma require biologic drugs as add-on therapy. In the past decade, numerous monoclonal antibodies have been approved for children or adolescents with severe asthma, in addition to their increasing use in adult asthma. However, the available evidence on how to select the most appropriate biologic based on a single patient's clinical, functional, and laboratory characteristics is still scant, and is insufficient to guide clinicians in the decision-making process of a personalized treatment. Materials and methods: We report a case series of four patients with severe eosinophilic asthma treated with mepolizumab, an anti-interleukin-5 monoclonal antibody, and review the existing literature on this treatment in children and adolescents. Results: Our patients, all with blood eosinophilia and elevated fractional exhaled nitric oxide levels, developed poor symptom control despite prolonged treatment with high-dose inhaled corticosteroids plus a second controller, addressing the addition of a biologic drug. In all of them, a 12-month treatment with subcutaneous mepolizumab showed a reduction in the blood eosinophil count and in asthma exacerbations, as well as an improvement on the Asthma Control Test. The results of the literature search focused on the strengths and limitations of the pediatric use of mepolizumab and highlighted the areas worthy of further research. Conclusions: Mepolizumab has proven effective in improving symptom control in pediatric patients with severe asthma. Additional well-powered clinical trials will be helpful in developing evidence-based guidelines regarding biologic drugs in the pediatric population.
Efficacy and Safety of Benralizumab for Eosinophilic Asthma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Bao-ping Tian,Gen-sheng Zhang,Jian Lou,Hong-bin Zhou,Wei Cui

DOI: https://doi.org/10.1080/02770903.2017.1379534

2017-01-01

Abstract:Context: Benralizumab is a humanized monoclonal antibody that targets the alpha chain of the IL-5 receptor (IL-5R alpha) and is currently being assessed in clinical trials for asthma control. Objective: Our systematic review and meta-analysis intends to evaluate the therapeutic efficacy and safety of benralizumab in patients with eosinophilic asthma. Data sources and extraction: Literature searches of PubMed, Embase, and the Cochrane Library were performed to identify randomized controlled trials of benralizumab and clinic outcomes in asthmatics. Results: In total, 7 articles with 2,321 subjects met our inclusion criteria. From this pooled analysis, we found that benralizumab significantly reduces exacerbations (RR: 0.63, 95% CI: 0.52-0.76, p < 0.00001; l(2) = 52%, p = 0.06) compared to placebo in eosinophilic asthma. There was no statistical trend for improvement in forced expiratory volume in 1 second or asthma control indices such as Quality of Life Assessment (AQLQ) and Asthma Control Questionnaire score in benralizumab-treated patients. In addition, safety data indicated that benralizumab administration resulted no increasing incidence of adverse events and was well tolerated (RR: 1.00, 95% CI: 0.95-1.05, p = 0.96; l(2) = 40%, p = 0.13). Conclusion: These results demonstrate the efficacy and safety of benralizumab for asthma patients with severe or uncontrolled symptoms and elevated eosinophils and provide support for benralizumab as an ideal option to treat asthma in this patient population.
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

Ian D Pavord,Pascal Chanez,Gerard J Criner,Huib A M Kerstjens,Stephanie Korn,Njira Lugogo,Jean-Benoit Martinot,Hironori Sagara,Frank C Albers,Eric S Bradford,Stephanie S Harris,Bhabita Mayer,David B Rubin,Steven W Yancey,Frank C Sciurba

DOI: https://doi.org/10.1056/NEJMoa1708208

2017-10-26

Abstract:Background: Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5. Methods: We performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in patients with COPD who had a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy. In METREX, unselected patients in the modified intention-to-treat population with an eosinophilic phenotype were stratified according to blood eosinophil count (≥150 per cubic millimeter at screening or ≥300 per cubic millimeter during the previous year). In METREO, all patients had a blood eosinophil count of at least 150 per cubic millimeter at screening or at least 300 per cubic millimeter during the previous year. The primary end point was the annual rate of moderate or severe exacerbations. Safety was also assessed. Results: In METREX, the mean annual rate of moderate or severe exacerbations in the modified intention-to-treat population with an eosinophilic phenotype (462 patients) was 1.40 per year in the mepolizumab group versus 1.71 per year in the placebo group (rate ratio, 0.82; 95% confidence interval [CI], 0.68 to 0.98; adjusted P=0.04); no significant between-group differences were found in the overall modified intention-to-treat population (836 patients) (rate ratio, 0.98; 95% CI, 0.85 to 1.12; adjusted P>0.99). In METREO, the mean annual rate of moderate or severe exacerbations was 1.19 per year in the 100-mg mepolizumab group, 1.27 per year in the 300-mg mepolizumab group, and 1.49 per year in the placebo group. The rate ratios for exacerbations in the 100-mg and 300-mg mepolizumab groups versus the placebo group were 0.80 (95% CI, 0.65 to 0.98; adjusted P=0.07) and 0.86 (95% CI, 0.70 to 1.05; adjusted P=0.14), respectively. A greater effect of mepolizumab, as compared with placebo, on the annual rate of moderate or severe exacerbations was found among patients with higher blood eosinophil counts at screening. The safety profile of mepolizumab was similar to that of placebo. Conclusions: Mepolizumab at a dose of 100 mg was associated with a lower annual rate of moderate or severe exacerbations than placebo among patients with COPD and an eosinophilic phenotype. This finding suggests that eosinophilic airway inflammation contributes to COPD exacerbations. (Funded by GlaxoSmithKline; METREX and METREO ClinicalTrials.gov numbers, NCT02105948 and NCT02105961 .).
Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma

Jared Silver,Andrea Steffens,Benjamin Chastek,Arijita Deb

DOI: https://doi.org/10.2147/jaa.s444693

2024-03-24

Journal of Asthma and Allergy

Abstract:Jared Silver, 1 Andrea Steffens, 2 Benjamin Chastek, 2 Arijita Deb 3 1 Medical Affairs, GSK, Durham, NC, USA; 2 Optum, Eden Prairie, MN, USA; 3 Value, Evidence and Outcomes, GSK, Upper Providence, PA, USA Correspondence: Arijita Deb, Value, Evidence and Outcomes, GSK, 1250 S Collegeville Road, Upper Providence, PA, 19426, USA, Tel +1 267 377-5717, Email Purpose: Real-world data on mepolizumab in patients with severe asthma and allergic and non-allergic phenotypes are limited. This study investigated the effectiveness of mepolizumab treatment in patients with severe asthma with allergic and non-allergic phenotypes. Patients and Methods: This retrospective cohort study (GSK ID: 214148) used administrative claims data from the Optum Research Database. Eligible patients were ≥ 6 years of age with asthma and had ≥ 2 mepolizumab claims post-index. Index date was the first mepolizumab claim/administration (January 2016–December 2018). Patients were divided into two cohorts: allergic and non-allergic asthma, based on diagnosis codes, medication use and lab test results. Outcomes included the rate of asthma-related exacerbations and oral corticosteroid (OCS) use during the 12 months before (baseline period) and 12 months after (follow-up period) mepolizumab initiation. Study ended in December 2019. Results: Overall, 240 (44.6%) and 298 (55.4%) patients were included in the allergic and non-allergic asthma cohorts, respectively. Mean (standard deviation [SD]) counts of asthma-related exacerbations were significantly reduced from baseline to follow-up in both the allergic and non-allergic asthma cohorts (3.2 [2.5] to 2.1 [2.1], p < 0.001 and 2.5 [2.2] to 1.7 [1.9], p < 0.001, respectively). The mean number of OCS pharmacy claims was significantly decreased by 33.3% and 41.4% from baseline to follow-up in the allergic and non-allergic cohorts, respectively (p < 0.001); mean daily OCS dose significantly decreased by 30.6% and 45.4%, respectively (p < 0.001) as well as the mean number of OCS bursts, which decreased by 44.9% and 41.8%, respectively (p < 0.001). No significant differences were observed between cohorts in reductions in asthma exacerbations, counts of OCS pharmacy claims or OCS bursts (baseline to follow-up). Conclusion: Mepolizumab significantly reduced asthma exacerbations and OCS use in patients with allergic and non-allergic asthma, suggesting that mepolizumab provides real-world benefit in severe asthma irrespective of whether a patient has an allergic phenotype. Keywords: severe asthma, phenotype, exacerbation, oral corticosteroid Severe asthma is characterized by treatment with high-dose inhaled corticosteroids (ICS) in addition to a second controller and/or systemic corticosteroids (SCS), including oral corticosteroids (OCS). 1 However, symptoms may remain uncontrolled leading to frequent asthma exacerbations requiring short-acting ß 2 -agonist (SABA) and OCS use, emergency treatment, or hospitalization. 1,2 Severe asthma can be classified by phenotype including those with elevated sputum and/or blood eosinophil counts (severe asthma with an eosinophilic phenotype) or sensitivity to environmental allergens plus elevated immunoglobulin E (IgE) levels (severe allergic asthma). 3–5 These phenotypes share features including being mechanistically driven by type 2 inflammation and the presence of elevated eosinophil counts. 5 Approximately three-quarters of patients with severe asthma with an eosinophilic phenotype also have an allergic phenotype. 6 Treatments targeting the common mechanisms underlying phenotypes, such as elevated eosinophil counts, plausibly provide benefit across asthma phenotypes. 5 Mepolizumab is a humanized monoclonal antibody approved in Europe and the USA as an add-on therapy for the treatment of severe asthma. 7,8 By specifically targeting interleukin (IL)-5, a cytokine that promotes differentiation, activation, and eosinophil survival, mepolizumab enables a precision medicine approach to eosinophilic disease. 9–11 Mepolizumab efficacy in patients with severe asthma is well documented in clinical trials, 12–14 post hoc analyses of clinical trials, 15,16 and real-world studies. 17–20 However, most data on mepolizumab efficacy in patients with and without allergic phenotypes is limited to clinical studies. Post hoc analyses of the DREAM (NCT01000506), MENSA (NCT01691521), and MUSCA (NCT02281318) clinical trials demonstrated similar clinical benefit of mepolizumab in patients with severe asthma irrespective of atopic status, prior omalizumab use, IgE level and sensitivity to particular allergens.<s -Abstract Truncated-

immunology,allergy,respiratory system
Real-world Effectiveness of Mepolizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-analysis

Hongwen Li,Qing Zhang,Jingru Wang,Shengnan Gao,Chunxiao Li,Jianxin Wang,Shuhua Zhang,Jiangtao Lin

DOI: https://doi.org/10.1016/j.clinthera.2021.03.023

IF: 3.637

2021-06-01

Clinical Therapeutics

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>Mepolizumab is a human monoclonal antibody against interleukin 5 (IL-5) used to treat severe eosinophilic asthma. Several studies have evaluated the effectiveness of mepolizumab in the real world. We conducted a systematic review and meta-analysis in the context of heterogeneity among patients, clinicians, and treatment regimens to study the effectiveness of mepolizumab in the real world.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We searched the PubMed and Embase databases for real-world studies on severe asthma treatment with mepolizumab as of June 30, 2020. Exacerbations, asthma-related hospitalizations, forced expiratory volume in 1 second (FEV<sub>1</sub>), Asthma Control Questionnaire (ACQ) or Asthma Control Test (ACT), corticosteroid use, peripheral blood eosinophil counts, and the fraction of exhaled nitric oxide were selected as indicators to evaluate the effectiveness. Standardized mean differences by the Cohen method and mean differences were chosen as indicators of effect size. Cohen <em>d</em> values of 0.2, 0.5, and 0.8 are considered as small, medium, and large effects, respectively. We used the Dersimonian-Laird random-effect model to quantify pooled effectiveness estimates.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Findings</h3><p>A total of 1457 patients from 13 studies were included in this review. At all time points, mepolizumab was associated with reductions in exacerbations (2.92 and 2.73 events per patient per year fewer at 6 and 12 months, respectively) and hospitalizations (0.36 events per patient per year fewer at 12 months); improvements in asthma control (ACQ scores reductions of 1.32 and 1.03 at 6 and 12 months, respectively; ACT scores increase of 6.52 at 6–12 months); slight improvements in pulmonary function (FEV<sub>1</sub> increase of 0.23 L at 1–3 months and 6–12 months, respectively); reductions in oral corticosteroid use (9.02- and 7.68-mg decrease at 6 and 12 months, respectively); and reductions in peripheral blood eosinophil counts (decreases of 559.11 cells/μL and 599.17 cells/μL at 1–3 months and 6–12 months, respectively) and fraction of exhaled nitric oxide (13-ppb reduction at 6–12 months).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Implications</h3><p>Our study suggests that mepolizumab is associated with improvements in several clinically meaningful real-world outcomes. This study is a supplement to and extension of the efficacy of randomized controlled trials of mepolizumab. (<em>Clin Ther</em>. 2021;XX:XXX–XXX) © 2021 Elsevier HS Journals, Inc.</p>

pharmacology & pharmacy
Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases

Francesco Menzella,Mirco Lusuardi,Carla Galeone,Sofia Taddei,Luigi Zucchi

DOI: https://doi.org/10.2147/JAA.S40244

2015-10-08

Abstract:Asthma is a complex disorder frequently associated with a poor symptom control, concomitant morbidity, mortality, and significant health care costs due to lack of compliance or inadequate therapeutic options. Interleukin-5 (IL-5) plays a key role in the pathogenesis of eosinophilic disorders, and in the latest years has become a definite target for treatment. Besides asthma, other hypereosinophilic disorders include the hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, sinonasal polyposis, COPD with eosinophilic airway inflammation, allergic rhinitis, atopic dermatitis, eosinophilic esophagitis. The introduction of mepolizumab, a fully humanized monoclonal antibody that binds to IL-5, may represent a useful therapeutic option to control exacerbations and improve asthma-related quality of life in a subgroup of patients with persistent airway eosinophilia and moderate to severe asthma. Several studies carried out in recent years allow, at present, a careful patient selection for appropriate individualized treatment in severe asthma. Further research is anyway needed in order to better understand the pathogenetic mechanisms of asthma and to find new biomarkers. The high costs of biological agents as compared with standard drugs may be largely offset by increased clinical efficacy and good safety profile in selected patients.
Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Kenneth R. Chapman,Kathryn Cogger,Erin Arthurs,Callahan LaForty,Shane Golden,Bradley Millson,Koyo Usuba,Christopher Licskai

DOI: https://doi.org/10.1186/s13223-023-00863-7

2024-02-06

Allergy Asthma & Clinical Immunology

Abstract:Mepolizumab, the first widely available anti-interleukin 5 biologic, targets eosinophilic inflammation and has been shown in clinical trials to reduce exacerbations, oral corticosteroid dependence, and healthcare utilization in patients with severe asthma. The impact of mepolizumab in a real-world, publicly funded healthcare setting is unknown. The objective of this study was to describe the demographics and clinical characteristics of real-world patients receiving mepolizumab, and to compare asthma-related outcomes and associated asthma-related costs before and during mepolizumab use.

immunology,allergy
Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial

Victoria Cornelius,Daphne Babalis,William D Carroll,Steven Cunningham,Louise Fleming,Erol Gaillard,Atul Gupta,Leila Janani,Erika Kennington,Clare Murray,Prasad Nagakumar,Graham Roberts,Paul Seddon,Ian Sinha,Claire Streatfield,Elise Weir,Sejal Saglani

DOI: https://doi.org/10.1136/bmjopen-2024-090749

IF: 3.006

2024-08-21

BMJ Open

Abstract:Introduction: A minority of school-aged children with asthma have persistent poor control and experience frequent asthma attacks despite maximal prescribed maintenance therapy. These children have higher morbidity and risk of death. The first add-on biologic therapy, omalizumab, a monoclonal antibody that blocks immunoglobulin (Ig)E, was licensed for children with severe asthma in 2005. While omalizumab is an effective treatment, non-response is common. A second biologic, mepolizumab which blocks interleukin 5 and targets eosinophilic inflammation, was licensed in 2018, but the licence was granted by extrapolation of adult clinical trial data to children. This non-inferiority (NI) trial will determine whether mepolizumab is as efficacious as omalizumab in reducing asthma attacks in children with severe therapy resistant asthma (STRA) and refractory difficult asthma (DA). Methods and analysis: This is an ongoing multicentre 1:1 randomised NI open-label trial of mepolizumab and omalizumab. Up to 150 children and young people (CYP) aged 6-17 years with severe asthma will be recruited from specialist paediatric severe asthma centres in the UK. Prior to randomisation, children will be monitored for medication adherence for up to 16 weeks to determine STRA and refractory DA diagnoses. Current prescribing recommendations of serum IgE and blood eosinophils will not influence eligibility or enrolment. The primary outcome is the 52-week asthma attack rate. Bayesian analysis using clinician-elicited prior distributions will be used to calculate the posterior probability that mepolizumab is not inferior to omalizumab. Secondary outcomes include Composite Asthma Severity Index, Paediatric Asthma Quality of Life Questionnaire, lung function measures (forced expiratory volume in one second (FEV1), bronchodilator reversibility), fractional exhaled nitric oxide, Asthma Control Test (ACT), health outcomes EuroQol 5 Dimension (EQ-5D) and optimal serum IgE and blood eosinophil levels that may predict a response to therapy. These outcomes will be analysed in a frequentist framework using longitudinal models. Ethics and dissemination: The study has been approved by the South Central-Berkshire Research Ethics Committee REC Number 19/SC/0634 and had Clinical Trials Authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) (EudraCT 2019-004085-17). All parents/legal guardians will give informed consent for their child to participate in the trial, and CYP will give assent to participate. The results will be published in peer-reviewed journals, presented at international conferences and disseminated via our patient and public involvement partners. Trial registration number: ISRCTN12109108; EudraCT Number: 2019-004085-17.
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study

Claudia Crimi,Santi Nolasco,Alberto Noto,Angelantonio Maglio,Vitaliano Nicola Quaranta,Danilo Di Bona,Giulia Scioscia,Francesco Papia,Maria Filomena Caiaffa,Cecilia Calabrese,Maria D’Amato,Corrado Pelaia,Raffaele Campisi,Carolina Vitale,Luigi Ciampo,Silvano Dragonieri,Elena Minenna,Federica Massaro,Lorena Gallotti,Luigi Macchia,Massimo Triggiani,Nicola Scichilone,Giuseppe Valenti,Girolamo Pelaia,Maria Pia Foschino Barbaro,Giovanna Elisiana Carpagnano,Alessandro Vatrella,Nunzio Crimi

DOI: https://doi.org/10.1101/2024.03.13.24304254

IF: 11.022

2024-08-29

The Journal of Allergy and Clinical Immunology In Practice

Abstract:ABSTRACT Background Biological therapies, such as mepolizumab, have transformed the treatment of severe eosinophilic asthma. While mepolizumab’s short-term effectiveness is established, there is limited evidence on its ability to achieve long-term clinical remission. Objective To evaluate the long-term effectiveness and safety of mepolizumab, explore its potential to induce clinical and sustained remission, and identify baseline factors associated with the likelihood of achieving remission over 24 months. Methods The REMI-M is a retrospective, real-world, multicenter study that analyzed 303 severe eosinophilic asthma patients who received mepolizumab. Clinical, demographic, and safety data were collected at baseline, 3, 6, 12, and 24 months. The most commonly used definitions of clinical remission, which included no exacerbations, no oral corticosteroids (OCS) use, and good asthma control with or without assessment of lung function parameters, were adopted. Sustained remission was defined as reaching clinical remission at 12 months and maintaining it until the end of the 24-month period. Results Clinical remission rates ranged from 28.6% to 43.2% after 12 months and from 26.8% to 52.9% after 24 months, based on the different remission definitions. The proportion of patients achieving sustained remission varied between 14.6% to 29%. Factors associated with the likelihood of achieving clinical remission included the presence of aspirin-exacerbated respiratory disease, better lung function, male sex, absence of anxiety/depression, gastro-esophageal reflux disease, bronchiectasis, and reduced OCS consumption. Adverse events were infrequent. Conclusions This study demonstrates the real-world effectiveness of mepolizumab in achieving clinical remission and sustained remission in severe eosinophilic asthma over 24 months. The identification of distinct factors associated with the likelihood of achieving clinical remission emphasizes the importance of comprehensive management of comorbidities and timely identification of patients who may benefit from biologics. HIGHLIGHTS BOX What is already known about this topic? Mepolizumab, an anti-IL-5 monoclonal antibody, has been shown to induce clinical remission after 12 months of treatment. However, long-term evidence remains limited. What does this article add to our knowledge? The REMI-M study investigated the effectiveness of mepolizumab in achieving clinical and sustained remission over 24 months. How does this study impact current management guidelines? Mepolizumab can elicit long-term clinical and sustained remission in a conspicuous proportion of patients with severe eosinophilic asthma, supporting its role as a possible disease-modifying agent. Management of comorbidities and timely identification of patients who may benefit from biological treatment are crucial for optimizing long-term outcomes.

immunology,allergy
Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies

Mi-Kyeong Kim,Hae-Sim Park,Choon-Sik Park,Soung-Jun Min,Frank C Albers,Steven W Yancey,Bhabita Mayer,Namhee Kwon

DOI: https://doi.org/10.3904/kjim.2019.198

Abstract:Background/aims: The efficacy and safety of mepolizumab in patients with severe eosinophilic asthma has been evaluated in a global clinical trial programme. This post hoc analysis assesses the efficacy and safety of mepolizumab in Korean patients. Methods: Data from Korean patients in the Phase III, placebo-controlled, randomised DREAM (MEA112997/NCT01000506) and MENSA (MEA115588/ NCT01691521) studies were included. Patients ≥ 12 years old with severe eosinophilic asthma received mepolizumab (DREAM: 75, 250 or 750 mg intravenously [IV]; MENSA: 75 mg IV or 100 mg subcutaneously [SC]), or placebo every 4 weeks for 52 weeks (DREAM) or 32 weeks (MENSA). The primary outcome was the rate of clinically significant asthma exacerbations. Secondary outcomes included forced expiratory volume in 1 second (FEV1), Asthma Control Questionnaire (ACQ) and St George's Respiratory Questionnaire (SGRQ) scores (MENSA only). Blood eosinophil counts (BEC) and safety were assessed throughout. Results: Reductions in the rate of clinically significant asthma exacerbations were observed with the approved (100 mg SC) and bioequivalent (75 mg IV) doses of mepolizumab in Korean patients who participated in DREAM and MENSA. In MENSA, trends for improvements from baseline at week 32 in pre-bronchodilator FEV1 (75 mg IV group), ACQ-5 and SGRQ scores (in both treatment groups) were seen versus placebo in Korean patients. Incidence of on-treatment adverse events was similar in Korean patients versus non-Korean patients as were observed reductions from baseline in BEC. Conclusion: Mepolizumab treatment provided clinical benefits for Korean patients with severe eosinophilic asthma; the safety profile is consistent with the overall population.
Mepolizumab in patients with asthma and features of COPD: A MENSA/MUSCA post hoc analysis

Pavord,I. D.,Howarth,P.,Chan,R.,Yang,S.,Kolterer,S.,Zhang,L.,Chupp,G.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4492

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Mepolizumab improved exacerbation rate and quality of life vs standard of care (SOC) in patients with severe asthma in Phase 3/4 studies MENSA/MUSCA (NCT01691521/NCT02281318). Aims and Objectives: Assess the effect of mepolizumab in patients with severe asthma stratified by presence/absence of COPD-like features (CLF). Methods: Post hoc analysis included patients receiving mepolizumab (100 mg SC) or SOC Q4W for 32 or 24 weeks (MENSA/MUSCA). CLFs were defined as aged ≥40 years, FEV1/FVC <0.7, post-bronchodilator (BD) predicted FEV1 <80% and poor BD reversibility <12% or 200 mL. Endpoints included change from baseline in annual exacerbation rate (AER), SGRQ score and pre-BD FEV1. Results: At baseline, 83/468 patients receiving mepolizumab had CLF vs 104/468 for SOC. AER was significantly reduced from baseline with mepolizumab vs SOC (pooled MENSA/MUSCA; rate ratio [95% CI]: 0.45 [0.28, 0.71] with CLF vs 0.43 [0.34, 0.55] without). SGRQ score similarly improved from baseline with mepolizumab vs SOC for those with and without CLF in MENSA (difference [95% CI]: –10.1 [–21.5, 1.2] vs –6.6 [–9.9, –3.2]) and MUSCA (–8.3 [–13.7, –2.9] vs –8.1 [–11.3, –4.8]). Similar FEV1 improvements were seen in both CLF groups (Figure). Conclusions: With mepolizumab, exacerbation rate, SGRQ and lung function were similarly improved for patients with and without CLF.

respiratory system
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

Mark C Liu,Bradley Chipps,Xavier Munoz,Gilles Devouassoux,Miguel Bergna,Steven G Smith,Robert G Price,Dmitry V Galkin,Jay Azmi,Dalal Mouneimne,Frank C Albers,Kenneth R Chapman

DOI: https://doi.org/10.1186/s12931-021-01733-9

2021-05-10

Abstract:Background: The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four efficacy outcomes and the relationship between patient baseline characteristics and treatment response. Methods: This was a post hoc analysis of OSMO study data (GSK ID:204471; ClinicalTrials.gov No. NCT02654145). Patients with severe eosinophilic asthma uncontrolled by high-dose inhaled corticosteroids, other controller(s) and omalizumab subcutaneously (≥ 4 months) were switched to mepolizumab 100 mg administered subcutaneously. Endpoints included the proportion of responders-i.e. patients achieving a pre-defined clinical improvement in ≥ 1 of the following outcomes: (1) Asthma Control Questionnaire (ACQ)-5 score (≥ 0.5-points), (2) St George's Respiratory Questionnaire (SGRQ) total score (≥ 4-points), (3) pre-bronchodilator forced expiratory volume in 1s (FEV1; ≥ 100 mL), all at Week 32, and (4) annualised rate of clinically significant exacerbations (≥ 50% reduction). Results: Of the 145 patients included, 94%, 83%, 63% and 31% were responders for ≥ 1, ≥ 2, ≥ 3 and 4 outcomes, respectively; 75% and 78% were ACQ-5 and SGRQ score responders, and 50% and 69% were FEV1 and exacerbation responders. Subgroup analyses demonstrated improvements irrespective of baseline blood eosinophil count, prior omalizumab treatment regimen/duration, comorbidities, prior exacerbation history, maintenance oral corticosteroid use, ACQ-5 and SGRQ scores, and body weight/body mass index. Conclusions: After switching to mepolizumab, almost all patients with uncontrolled severe eosinophilic asthma on omalizumab achieved a beneficial response in ≥ 1 clinical outcome. Improvements were observed regardless of baseline characteristics. Trial registration This manuscript is a post hoc analysis of data from the OSMO study. ClinicalTrials.gov, NCT02654145. Registered January 13, 2016.
Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series

Carlo Lombardi,Francesco Menzella,Alvise Berti

DOI: https://doi.org/10.7573/dic.2024-4-2

2024-07-22

Abstract:Background: Patients with severe asthma are often dependent on oral corticosteroids (OCS) and have frequent exacerbations. This article aims to report very long-term data of patients with severe eosinophilic asthma assessing asthma control, lung function, inhaled corticosteroid (ICS) dose reduction, and clinical and biological parameters of patients treated with mepolizumab. Methods: Four cases of adult patients with severe eosinophilic asthma who were treated for 60 months or more with mepolizumab 100 mg/4 weeks, leading to the stable discontinuation of OCS, are presented. ICS dose, OCS dose and withdrawal date, lung function, eosinophil count, fractional exhaled nitric oxide, and asthma control test were recorded as well as exacerbations in the 12 months before commencing mepolizumab and in the 12 months before the last follow-up visit. Results: Three of the patients were men, median age was 52.5 years (range 79-53), median length of asthma before mepolizumab start was 67.5 months (range 24-240), three had chronic rhinosinusitis without nasal polyposis and two were atopic. All had eosinophil counts >300 cells/μL at baseline. The median follow-up was 73.5 months (range 71-74), and OCS withdrawal from baseline occurred after a median of 13 months of mepolizumab treatment (range 12-39). A substantial reduction of ICS treatment was registered as well as improvement in asthma control test, fractional exhaled nitric oxide and functional parameters, and a significant reduction of exacerbations in the last 12 months before last visit was observed as compared to the 12 months before baseline (from a median of 4 (range 3-6) to 0; p=0.0286). Conclusions: Mepolizumab could be a 'disease-modifying' agent, with high tolerability and a good efficacy profile in the long term.
Mepolizumab response in patients with COPD and an eosinophilic phenotype with/without chronic bronchitis (CB): A METREX/METREO post hoc analysis

Vogelmeier,C.,Stolz,D.,Roche,N.,Mc Cormack,M. C.,Chan,R.,Kolterer,S.,Mayer,B.,Papi,A.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4783

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Mepolizumab reduced annual moderate/severe exacerbation rates (AER) vs placebo in COPD with an eosinophilic phenotype in the METREX/METREO Phase 3 trials (NCT02105948/NCT02105961). Aims and Objectives: To assess mepolizumab efficacy in COPD with an eosinophilic phenotype with/without CB symptoms. Methods: Post hoc analysis of METREX/METREO in those with a screening blood eosinophil count (BEC; cells/μL) ≥300 receiving mepolizumab (100 mg SC) or placebo Q4W for 52 weeks, with/without CB symptoms based on SGRQ. Endpoints included AER at Week 52, COPD Assessment Test (CAT) responders (≥2-point improvement), CAT score change from baseline at Weeks 48–52, and SGRQ responders (≥4-point reduction) at Week 52. Results: At baseline, 161/456 (35%) and 175/455 (38%) in mepolizumab and placebo groups had a screening BEC ≥300 and available data to assess CB symptoms. Of these, 99/161 (61%) and 115/175 (66%) reported CB symptoms, respectively. AER with mepolizumab vs placebo was 1.32 vs 1.73 (rate ratio [95% CI]: 0.76 [0.56, 1.03]) with CB and 1.25 vs 1.63 (0.76 [0.51, 1.14]) without. CAT patient responder rates were 53% vs 40% with CB (OR [95% CI]: 1.71 [0.97, 3.01]) and 28% vs 34% (0.57 [0.24, 1.35]) without. Difference in change in CAT score (95% CI) was -1.9 (–3.7, –0.1) with CB and –0.5 (–2.8, 1.7) without. SGRQ responders totalled 48% vs 36% for mepolizumab vs placebo with CB (OR [95% CI]: 1.63 [0.93, 2.84]), and 48% vs 50% without (0.94 [0.42, 2.10). Conclusions: Mepolizumab reduced exacerbations regardless of CB symptoms, while CAT and SGRQ responses were more pronounced in patients with CB.

respiratory system
A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Huqun Li,Chongshu Wang,Aiping Deng,Cuilian Guo

DOI: https://doi.org/10.3389/fphar.2023.1280490

2023-12-07

Abstract:Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-related adverse events based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: A disproportionality analysis was performed to assess the safety profile of mepolizumab based on the reports from the FAERS database between October 2015 and December 2022. Demographic information, the time to onset, the safety of long-term mepolizumab exposure as well as safety in pediatric patients were also investigated. Results: A total of 736 significant preferred terms (PTs) were identified among the 13,497 mepolizumab-associated adverse events (AEs) reports collected from the FAERS database. The frequently reported AEs including dyspnea, fatigue, and headache were in line with drug instruction and previous studies. Unexpected significant AEs such as cough, malaise, and chest discomfort were also identified. Most AEs occurred within the first month after mepolizumab initiation. Pneumonia and wheezing were frequently reported in patients with long-term mepolizumab exposure as well as in the pediatric population. Conclusion: Our results were consistent with the observations in previous clinical and real-world studies. New and unexpected AE signals of mepolizumab were also identified. Close attention should be paid to the long-term safety of mepolizumab as well as safety in the pediatric population. Prospective studies are required for optimal use of mepolizumab.
Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Ian Pavord,Robert Chan,Nicola Brown,Peter Howarth,Martyn Gilson,Robert G. Price,Jorge Maspero

DOI: https://doi.org/10.1080/07853890.2024.2417184

IF: 5.348

2024-10-29

Annals of Medicine

Abstract:Objectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult patients with severe asthma.

medicine, general & internal
Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial

Ruchong Chen,Liping Wei,Yuanrong Dai,Zaiyi Wang,Danrong Yang,Meiling Jin,Cui Xiong,Ting Li,Shuling Hu,Jie Song,Robert Chan,Subramanya Kumar,Azza Abdelkarim,Nanshan Zhong

DOI: https://doi.org/10.1183/23120541.00750-2023

2024-05-20

Abstract:Background: In China, the prevalence of severe asthma with eosinophilic phenotype is rising, yet treatment options are limited. Mepolizumab is the first targeted biologic therapy for eosinophilic-driven disease in China. This study (clinicaltrials.gov identifier NCT03562195) evaluated efficacy and safety of mepolizumab in Chinese patients with severe asthma. Methods: The phase III, multicentre, randomised, placebo-controlled, double-blind, parallel-group study enrolled patients aged ≥12 years with severe asthma, with two or more exacerbations in the previous year, and on inhaled corticosteroids plus at least one controller medication. Following a 1-4-week run-in, patients were randomised 1:1 to mepolizumab 100 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end-point was annualised rate of clinically significant exacerbations (CSEs) through week 52. Secondary end-points were time to first CSE, frequency of CSEs requiring hospitalisation/emergency department visits or hospitalisation over 52 weeks, mean change in St George's Respiratory Questionnaire (SGRQ) total score and pre-bronchodilator forced expiratory volume in 1 s (FEV1) at week 52; safety was evaluated. Results: The modified intention-to-treat population included 300 patients. At week 52 with mepolizumab versus placebo, annualised rate of CSEs was 65% lower (0.45 versus 1.31 events per year; rate ratio 0.35, 95% CI 0.24-0.50; p<0.001); time to first CSE longer (hazard ratio 0.38, 95% CI 0.26-0.56; p<0.001) and number of CSEs requiring hospitalisation/emergency department visit lower (rate ratio 0.30, 95% CI 0.12-0.77; p=0.012). From baseline to week 52, SGRQ score improved (p=0.001) and pre-bronchodilator FEV1 increased (p=0.006). Incidence of adverse events was similar between treatment groups. Conclusion: Mepolizumab provided clinical benefits to patients with severe asthma in China and showed a favourable benefit-risk profile.
Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis

Charlene Desaintjean,Kaïs Ahmad,Julie Traclet,Mathieu Gerfaud-Valentin,Cecile-Audrey Durel,Jean-Charles Glerant,Arnaud Hot,François Lestelle,Sabine Mainbourg,Mouhamad Nasser,Pascal Seve,Ségolène Turquier,Gilles Devouassoux,Vincent Cottin

DOI: https://doi.org/10.3389/fmed.2024.1341310

IF: 3.9

2024-03-22

Frontiers in Medicine

Abstract:Introduction Asthma associated with eosinophilic granulomatosis with polyangiitis (EGPA) is often severe and corticosteroid-dependent, leading to significant morbidity. Mepolizumab and benralizumab are humanized monoclonal antibodies targeting interleukin 5 (IL-5) and its receptor, respectively. They have been shown to be effective in steroid-sparing in patients with severe eosinophilic asthma. Objective Our aim was to evaluate the efficacy and safety of mepolizumab and benralizumab prescribed for severe asthma in patients with EGPA under “real-world” conditions. Methods This was a retrospective analysis of patients with EGPA and persistent asthma who received either mepolizumab 100 or 300 mg administered every 4 weeks, or benralizumab 30 mg administered every 4 weeks for the initial 3 injections and followed by an injection every 8 weeks thereafter, whilst combined with oral glucocorticoids. The follow-up every 6 ± 3 months included an assessment of clinical manifestations, pulmonary function tests and eosinophil cell count. The primary outcome was the proportion of patients at 12 months receiving a daily oral dose of prednisone or equivalent of 4 mg or less with a BVAS of 0. Results Twenty-six patients were included. After 12 months of treatment with mepolizumab or benralizumab, 32% of patients met the primary outcome and were receiving less than 4 mg of prednisone per day with a BVAS of 0. The median dose of prednisone was 10 mg per day at baseline, 9 mg at 6 months, and 5 mg at 12 months ( p ≤ 0.01). At 12 months, 23% of patients were weaned off corticosteroids, while an increase or no change in dose was observed in 27% of patients. The median eosinophil count was significantly reduced from 365 cells/mm 3 to 55 cells/mm 3 at 6 months and 70 cells/mm 3 at 12 months, respectively. No significant change was observed in FEV1. After 12 months of treatment, 14% of patients had had an average of 1 exacerbation of asthma, compared with 52% of patients before baseline. The tolerability profile was favorable. Conclusion In this real-world study in patients with severe asthma and a history of EGPA asthma, mepolizumab and benralizumab had a significant steroid-sparing effect and reduced asthma exacerbation, but no significant effect on lung function.

medicine, general & internal
Effectiveness of Mepolizumab in patients with late-onset severe eosinophilic asthma and fixed obstruction, a 2-Year Follow-Up: The MESILICO study

Porpodis,K.,Tsiouprou,I.,Damdoumis,S.,Bakakos,P.,Steiropoulos,P.,Voulgaris,A.,Katsoulis,K.,Kipourou,M.,Kostikas,K.,Antoniou,K. M.,Papaioannou,A. I.,Rovina,N.,Katsaounou,P.,Tryfon,S.,Fouka,E.,Papakosta,D.,Loukides,S.,Domvri,K.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa5366

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Purpose: We investigated the efficacy of Mepolizumab treatment in severe asthmatics by assessing patient characteristics associated with treatment response. Methods: MESILICO is a multicenter study including 8 Pulmonary Clinics in Greece. Patients with late-onset severe eosinophilic asthma and fixed obstruction were eligible to be administered Mepolizumab. Forty-seven patients were recruited in MESILICO study. Clinical parameters such as spirometry values (FEV1, FVC, PEF, MEF), ACT value, biomarkers of inflammation (blood eosinophils, FENO, IgE) were evaluated before and after treatment initiation. This trial is registered with ClinicalTrials.gov, number NCT04612556. Results: Forty-five patients concluded 12 months of mepolizumab treatment. The majority of the asthmatics were women (85%) of mean age 57.4 ± 11 years. After 12 months, mepolizumab treatment was associated with clinical improvement, with, in comparison to the year pre-mepolizumab initiation, a significant reduction in severe disease exacerbation (67%) along with significant improvements in lung function and asthma control score (p<0.001). Mepolizumab treatment was also associated with a significant decrease in blood eosinophils and FeNO (p<0.001). Forty-three patients concluded 24 months of mepolizumab treatment. At 2-year follow-up, no significant changes were observed in all parameters, and clinical improvement was stable. No new safety signals were observed in this study. Conclusions: These data demonstrate that 2 years follow up of mepolizumab treatment improves the clinical outcomes of patients with late-onset severe eosinophilic asthma and fixed obstruction. Efficacy of mepolizumab in this real-world study is consistent with previous studies in other phenotypes of severe asthmatics. Funding: GSK 214163.

respiratory system

Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience

Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature

Efficacy and Safety of Benralizumab for Eosinophilic Asthma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma

Real-world Effectiveness of Mepolizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-analysis

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies

Mepolizumab in patients with asthma and features of COPD: A MENSA/MUSCA post hoc analysis

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series

Mepolizumab response in patients with COPD and an eosinophilic phenotype with/without chronic bronchitis (CB): A METREX/METREO post hoc analysis

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis

Effectiveness of Mepolizumab in patients with late-onset severe eosinophilic asthma and fixed obstruction, a 2-Year Follow-Up: The MESILICO study